SPPI logo

Spectrum Pharmaceuticals (SPPI) Stock

Profile

Full Name:

Spectrum Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 September 1996

Indexes:

Not included

Website:

http://www.sppirx.com

Description:

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Key Details

Price

-

Market Cap

-

Last Dividend

$0.15

TTM Dividend Yield

-

Annual Revenue

$10.11 M

Annual EPS

-$0.41(+59.80% YoY)

PE Ratio

-

Annual ROE

-199.89%

Annual Debt To Equity

1.03

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Aug 11, 2023

Recent annual earnings:

Mar 22, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Dec 18, 2012
Splits

Next split:

N/A

Recent split:

Sept 06, 2002

Analyst ratings

Recent major analysts updates

26 May '23 HC Wainwright & Co.
Neutral
15 May '23 Jefferies
Hold
26 Apr '23 JMP Securities
Market Perform
26 Apr '23 HC Wainwright & Co.
Neutral
06 Feb '23 JMP Securities
Market Outperform
03 Feb '23 Cantor Fitzgerald
Neutral
01 Feb '23 JMP Securities
Market Outperform
31 Jan '23 HC Wainwright & Co.
Buy
28 Nov '22 HC Wainwright & Co.
Buy
16 Nov '22 B. Riley Securities
Neutral

Screeners with SPPI included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$606.25
SPPI price is currently at an all-time high

Price Analysts Target

$1.14
SPPI price is currently equal to the consensus analysts' forecast

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Last Paid Dividend

$0.15
SPPI dividend per share is $0.15

Annual FCF

-$97.26 M
SPPI annual free cash flow is -$97.26 million

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue Estimate

$72.48 M
SPPI annual revenue is currently -86.05% lower than the consensus analysts' forecast

Annual Net Income 3-Year Change

+33.09%
SPPI annual net profit is up +33.09% over the past 3 years

Annual EPS 3-Year Change

+59.8%
SPPI annual earnings per share is up +59.8% over the past 3 years

Annual EPS Estimate

-$0.06
SPPI annual earnings per share is currently +583.33% higher than the consensus analysts' forecast

Annual Gross Profit

$8.32 M
SPPI annual gross profit is $8.32 million

Annual Operating Profit

-$72.70 M
SPPI annual operaing income is -$72.70 million

Annual Operating Profit 3-Year Change

+48.33%
SPPI annual operaing income is up +48.33% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-199.89%
SPPI annual return on equity is -199.89%

Annual ROA

-70.18%
SPPI annual return on assets is -70.18%

Annual EBIT

-$77.06 M
SPPI annual earnings before interest & taxes is -$77.06 million

Annual EBITDA

-$77.06 M
SPPI annual earnings before interest, taxes, depreciation & amortization is -$77.06 million

Annual Interest Coverage Ratio

-77.21
SPPI annual interest coverage ratio is -77.21

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Quick Ratio

2.15
SPPI annual quick ratio is 2.15

Annual Current Ratio

2.37
SPPI annual current ratio is 2.37

Annual Total Assets

$103.34 M
SPPI annual total assets is $103.34 million

Annual Current Assets

$101.01 M
SPPI annual total current assets is $101.01 million

Annual Total Liabilities

$75.45 M
SPPI annual total liabilities is $75.45 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+27.96%
SPPI annual cash flow from operations is up +27.96% over the past 3 years

Annual CFI 3-Year Change

-183.51%
SPPI annual cash flow from investing activities is down -183.51% over the past 3 years

Annual CFF 3-Year Change

+685.2%
SPPI annual cash flow from financing activities is up +685.2% over the past 3 years

Annual CAPEX

$273.00 K
SPPI annual capital expenditures is $273.00 thousand

Annual CAPEX 3-Year Change

-96.97%
SPPI annual capital expenditures is down -96.97% over the past 3 years

Annual FCF

-$97.26 M
SPPI annual free cash flow is -$97.26 million

Annual FCF 3-Year Change

+32.29%
SPPI annual free cash flow is up +32.29% over the past 3 years

Institutional Ownership

Similar stocks

Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
SPPI
businesswire.com25 June 2024

LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that it has completed enrollment in its Phase 1 trial (NCT06128382) with OVX033, the company's broad-spectrum vaccine candidate against sarbecoviruses. The study is designed to evaluate the safety and immunogenicity of OVX033 at three dose levels (100µg, 250µg and 500µg). To date, no safety concerns or signals ha.

Spectrum's Rolvedon A Differentiator In A $3B/Yr Market
Spectrum's Rolvedon A Differentiator In A $3B/Yr Market
Spectrum's Rolvedon A Differentiator In A $3B/Yr Market
SPPI
Seeking Alpha22 June 2023

Spectrum and Assertio's merger would lead to a diversified product portfolio and a combination of two unique marketing strategies. Spectrum's ROLVEDON has the potential to become the standard of care for reducing chemotherapy-induced neutropenia in a $3B domestic market. The combined companies of Assertio and Spectrum are estimated to provide a return of 4x.

Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates
Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates
Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates
SPPI
Zacks Investment Research09 May 2023

Spectrum Pharmaceuticals (SPPI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.

Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?
Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?
Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?
SPPI
InvestorPlace25 April 2023

Spectrum Pharmaceuticals (NASDAQ: SPPI ) stock is soaring higher on Tuesday thanks to an acquisition deal with Assertio (NASDAQ: ASRT ). This deal will have Assertio acquire all outstanding shares of SPPI stock.

FAQ

  • What is the primary business of Spectrum Pharmaceuticals?
  • What is the ticker symbol for Spectrum Pharmaceuticals?
  • Does Spectrum Pharmaceuticals pay dividends?
  • What sector is Spectrum Pharmaceuticals in?
  • What industry is Spectrum Pharmaceuticals in?
  • What country is Spectrum Pharmaceuticals based in?
  • When did Spectrum Pharmaceuticals go public?
  • Is Spectrum Pharmaceuticals in the S&P 500?
  • Is Spectrum Pharmaceuticals in the NASDAQ 100?
  • Is Spectrum Pharmaceuticals in the Dow Jones?
  • When was Spectrum Pharmaceuticals's last earnings report?
  • When does Spectrum Pharmaceuticals report earnings?
  • Should I buy Spectrum Pharmaceuticals stock now?

What is the primary business of Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

What is the ticker symbol for Spectrum Pharmaceuticals?

The ticker symbol for Spectrum Pharmaceuticals is NASDAQ:SPPI

Does Spectrum Pharmaceuticals pay dividends?

No, Spectrum Pharmaceuticals does not pay dividends

What sector is Spectrum Pharmaceuticals in?

Spectrum Pharmaceuticals is in the Healthcare sector

What industry is Spectrum Pharmaceuticals in?

Spectrum Pharmaceuticals is in the Biotechnology industry

What country is Spectrum Pharmaceuticals based in?

Spectrum Pharmaceuticals is headquartered in United States

When did Spectrum Pharmaceuticals go public?

Spectrum Pharmaceuticals's initial public offering (IPO) was on 26 September 1996

Is Spectrum Pharmaceuticals in the S&P 500?

No, Spectrum Pharmaceuticals is not included in the S&P 500 index

Is Spectrum Pharmaceuticals in the NASDAQ 100?

No, Spectrum Pharmaceuticals is not included in the NASDAQ 100 index

Is Spectrum Pharmaceuticals in the Dow Jones?

No, Spectrum Pharmaceuticals is not included in the Dow Jones index

When was Spectrum Pharmaceuticals's last earnings report?

Spectrum Pharmaceuticals's most recent earnings report was on 11 August 2023

When does Spectrum Pharmaceuticals report earnings?

The date for Spectrum Pharmaceuticals's next earnings report has not been announced yet

Should I buy Spectrum Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions